From: www.ecancer.tv on Fri, Apr 23 2010 1:16 PM

www.ecancer.tv

From: www.ecancer.tv on Fri, Apr 23 2010 10:26 AM

www.ecancer.tv

From: www.ecancer.tv on Fri, Apr 23 2010 10:26 AM

www.ecancer.tv

From: www.ecancer.tv on Fri, Apr 23 2010 10:26 AM

www.ecancer.tv

From: www.ecancer.tv on Fri, Apr 23 2010 10:26 AM

www.ecancer.tv

From: www.ecancer.tv on Fri, Apr 23 2010 10:26 AM

www.ecancer.tv

From: www.ecancer.tv on Fri, Apr 23 2010 10:26 AM

www.ecancer.tv

From: www.ecancer.tv on Thu, Apr 22 2010 1:28 PM

Dr Vanazzi discusses the trial investigating radioimmunotherapy with Y-90-ibritumomab tiuxetan in extranodal marginal zone lymphoma, a disease that currently has no standard treatment after primary therapies fail.Dr Anna Vanazzi of the European Institute of Oncology in Milan speaking at the ECCO...

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Dr Rejda discusses programmes devised to help people return to work after recovering from cancer.

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Dr Loibl talks about research indicating that using cytotoxic agents to treat pregnant women with breast cancer does not pose a threat to their unborn child.

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Professor Ganz discusses the post-treatment symptoms found in women who have survived breast cancer and the importance of managing these symptoms.

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Technical advances can lead to benefits for women, for instance marking areas most at risk of relapse to allow targeted radiotherapy, and using a small number of high dose radiotherapy fractions to more effectively treat breast cancer, resulting in an improved chance of the patient remaining fre...

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Professor O’Higgins, discusses the advantages of a centralised breast care services and his experiences helping to develop the national service in Ireland over the last 30 years.

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Kristina Desmedt discusses research that attempts to predict the efficacy of anthracyclines. The results of this study validate the use of topoisomerase II alpha as a predictive marker for the efficacy of anthracyclines. Further to this, the gene expression profiles in tumour biopsies were corre...

From: www.ecancer.tv on Thu, Apr 22 2010 8:16 AM

Dr Jones discusses the use of Trastuzumab (trade name Herceptin) and Lapatinib as drugs to target the HER2 receptor and the possibility of combining these as part of a dual targeting approach, the drawbacks including side effects or resistance among patients AND the services offered by HCA.

From: www.ecancer.tv on Tue, Apr 20 2010 12:01 PM

A study comparing FOLFIRI regimens with FOLFIRI plus panitumumab showed a two month increase in progression free survival among the patients with wild type KRAS treated with FOLFIRI plus panitumumab. Side effects are limited and manageable but include discomfort in the skin around the hands and f...

From: www.ecancer.tv on Tue, Apr 20 2010 9:22 AM

Ms Gore-Booth discusses the work of Europacolon and the challenges that have been faced raising awareness of colorectal cancer across Europe, the importance of patients to the communication of their message and her hopes for the first colorectal cancer conference which will be held in Lisbon.

From: www.ecancer.tv on Tue, Apr 20 2010 6:54 AM

Prof. Leer discusses the use of radiotherapy before rectal surgery, which part of rectum should be treated with preoperative radiotherapy and outlines the results of the recent TME clinical trials.

From: www.ecancer.tv on Tue, Apr 20 2010 6:54 AM

Professor van Cutsem discusses the importance of molecular markers in clinical practice, what factors are important in deciding the best treatment for colon cancer and how best to individualise and personalise cancer treatment. The first Europacolon patients meeting in Lisbon is discussed. This ...

From: www.ecancer.tv on Mon, Apr 19 2010 1:32 PM

Professor van de Velde offers an update on the progress of their international trial investigating whether preoperative radiotherapy is necessary when TME surgery is performed by a highly skilled surgeon. The importance of a skilled surgeon is stressed as an incredibly significant factor in the c...